Medical device manufacturers provide high quality imaging solutions for clinical assessment. While imaging capability is strong, clinical workflows can be enriched with automated AI, or services expanded to provide clinical decision support workflows.
RetinAI has certified AI solutions that provide automated analysis across disparate imaging datasets. Clinics can continue to use the imaging platforms they prefer, while benefiting from enhanced imaging capabilities for accelerating clinical studies, choosing treatments or monitoring outcomes.
RetinAI can provide a certified data management and AI software platform to integrate additional imaging devices within a clinical setting.
The platform is an open format that can connect to medical device manufacturers’ platform via API calls or via an existing PACS.
RetinAI has commercially-ready AI models to enhance imaging solutions already provided by manufacturers.
The AI is a value-add that medical device manufacturers can offer to clinics.
RetinAI’s certified AI can support patient identification for clinical studies or support physicians to assess outcomes based on retinal biomarkers, retinal fluid and OCT layer analysis.
RetinAI Discovery is a CE-marked medical device according to the Medical Devices Regulation (EU) 2017/745
and the AI models are CE-marked devices according to Medical Devices Directive 93/42/EEC
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
The AI modules for biomarkers, fluid and layer segmentation and quantification
in retinal pathologies are for research use only in the USA.
The Advanced Segmentation and GA modules are for research use only.
Please be advised these tools are not intended to be a substitute for medical advice, diagnosis or treatment.
We do not warrant any reliance on the accuracy, completeness or usefulness of any content.